Edwards Lifesciences vs ResMed|
Edwards Lifesciences and ResMed| are similar in size: $6.07bn and $5.65bn of revenue in their latest fiscal years. Edwards Lifesciences grew faster (11.5% against 9.9%). ResMed| kept more of each dollar of sales as profit: a net margin of 26.9% against 17.7%.
| Latest fiscal year | Edwards LifesciencesEW, 2025 | ResMed|RMD, 2026 |
|---|---|---|
| Revenue | $6.07bn | $5.65bn |
| Revenue growth | 11.5% | 9.9% |
| Net income | $1.07bn | $1.52bn |
| Operating margin | — | — |
| Net margin | 17.7% | 26.9% |
| Return on equity | 10.6% | 24.3% |
| Free cash flow | $1.33bn | $1.65bn |
| Cash | $2.94bn | $1.47bn |
| Total debt | $598m | $659m |
| Debt to equity | — | — |
| Dividend per share | — | $2.40 |
| Dividend yield | — | 1.1% |
| Share buybacks | $893m | $700m |
| Employees | 16,000 | 11,370 |
| Market value | $55.12bn | $31.58bn |
| Price vs our value range | Above our value range | Within our value range |
| Moat score | 96 (Strong) | 88 (Strong) |
| Insider trades, 12 months | 0 buys, 54 sales | 0 buys, 32 sales |